NIKKEI 225
38,054.13 -502.74 (-1.30%) HANG SENG
18,230.19 -246.82 (-1.34%) CRUDE OIL
77.71 -1.52 (-1.92%) GOLD FUTURES
2,366.20 +2.10 (+0.09%) DOW
38,153.40 -288.14 (-0.75%) Bitcoin GBP
54,359.27 +1,400.63 (+2.64%)
Harvard Bioscience, Inc. (HBIO)
| Previous close | 3.1000 |
| Open | 3.1000 |
| Bid | 3.1400 x 100 |
| Ask | 3.1900 x 100 |
| Day's range | 3.1000 - 3.2199 |
| 52-week range | 3.0900 - 6.2000 |
| Volume | |
| Avg. volume | 100,733 |
| Market cap | 137.02M |
| Beta (5Y monthly) | 1.46 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Harvard Bioscience, Inc. to Present at the Jefferies Global Healthcare Conference on June 5, 2024
HOLLISTON, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be presenting to investors at the Jefferies Global Healthcare Conference at the Marriott Marquis in New York City on June 5, 2024. The Company’s presentation will be 2:00-2:25 PM ET on June 5th. The presentation will be webcast live and can be accessed through the investor relations sectio
- GlobeNewswire
Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference
HOLLISTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Benchmark Healthcare House Call Virtual Conference on May 22nd, 2024, with a live fireside chat scheduled for 9:00-9:40 am ET. The Company will also be hosting one-on-one meetings with investors in conjunction with the Conference. To register for the presentation, o
- GlobeNewswire
Harvard Bioscience Announces First Quarter 2024 Financial Results
Strong gross margin performance and focus on efficiency to support ongoing investments in growthHOLLISTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2024. Jim Green, Chairman and CEO, said, “As expected, our first quarter revenues reflect ongoing market headwinds, especially in APAC, amplified by a strong prior year comparison. Despite these headwinds, we were pleased to
